ARMP
Armata Pharmaceuticals Inc
3.60$
-13.3%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 24.5% | 31.8% | 34.9% | 48.3% | 70.7% | 26.1% | 27.4% | 21.5% | 25.1% | 19.5% | 13.1% | 13.9% | |
| 23.0% | 29.8% | 31.4% | 46.1% | 68.6% | 23.7% | 24.4% | 14.7% | 13.8% | 13.7% | 10.7% | 11.3% | |
| 23.0% | 29.8% | 31.4% | 46.1% | 68.6% | 23.7% | 24.4% | 14.7% | 13.8% | 13.7% | 10.7% | 11.3% | |
| 0.3% | 0.4% | 0.1% | – | – | – | 1.4% | 4.3% | 7.9% | 3.4% | 0.9% | 0.6% | |
| – | – | -3.4% | – | – | – | -1.4% | -4.3% | – | – | – | – | |
| – | 3.6% | 5.9% | 34.3% | 27.3% | 16.6% | 32.5% | 3.2% | 3.4% | – | – | – | |
| 26.4% | 24.0% | 0.0% | – | – | 13.7% | 8.8% | 5.0% | 3.2% | 3.5% | 4.0% | 4.5% | |
| 44.8% | 40.6% | 59.2% | 44.3% | 25.0% | 40.3% | 26.0% | 14.7% | 9.5% | 10.4% | 11.9% | 13.3% | |
| 88.0% | 59.6% | 46.6% | 30.6% | 28.7% | 42.7% | 52.3% | 63.6% | 66.6% | 132.6% | 155.6% | 384.3% | |
| 6.5% | 7.6% | 19.7% | 17.7% | 21.6% | 19.2% | 17.0% | 6.9% | 23.1% | 16.7% | 55.8% | 11.6% | |
| – | – | 4.4% | 0.0% | – | 5.1% | 5.8% | 2.2% | 15.8% | 9.6% | 50.2% | 5.9% | |
| 4.1% | 3.3% | 5.8% | 5.2% | 6.1% | 2.1% | 2.4% | 1.6% | 1.6% | 1.6% | 0.9% | 1.2% | |
| – | – | – | – | – | – | – | – | – | 83.7% | 64.1% | 334.2% | |
| 12.0% | 40.4% | 53.4% | 69.4% | 71.3% | 57.3% | 47.7% | 36.4% | 33.4% | -32.6% | -55.6% | -284.3% | |
| -1,265.0% | -1,151.1% | -2,096.0% | -3,539.3% | -3,418.2% | -618.9% | -454.8% | -290.8% | -222.3% | -314.0% | -379.2% | -652.3% | |
| 0.2% | 0.1% | 0.0% | 4.1% | 2.8% | 30.8% | 41.5% | 34.5% | 31.8% | 36.7% | 41.8% | 47.1% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.